InvestorsHub Logo
Followers 33
Posts 2841
Boards Moderated 2
Alias Born 10/24/2015

Re: None

Thursday, 08/05/2021 1:04:04 PM

Thursday, August 05, 2021 1:04:04 PM

Post# of 97
At ESMO, Dr. Catenacci will give an oral presentation entitled: Clinical outcomes and immune responses in a Phase 1/2 study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GRTS News